Jeremy Whelan, Marie-Cecile Le Deley, Uta Dirksen, Gwénaël Le Teuff, Bernadette Brennan, Nathalie Gaspar, Douglas S Hawkins, Susanne Amler, Sebastian Bauer, Stefan Bielack, Jean-Yves Blay, Stefan Burdach, Marie-Pierre Castex, Dagmar Dilloo, Angelika Eggert, Hans Gelderblom, Jean-Claude Gentet, Wolfgang Hartmann, Wolf-Achim Hassenpflug, Lars Hjorth, Marta Jimenez, Thomas Klingebiel, Udo Kontny, Jarmila Kruseova, Ruth Ladenstein, Valerie Laurence, Cyril Lervat, Perrine Marec-Berard, Sandrine Marreaud, Jean Michon, Bruce Morland, Michael Paulussen, Andreas Ranft, Peter Reichardt, Hendrik van den Berg, Keith Wheatley, Ian Judson, Ian Lewis, Alan Craft, Heribert Juergens, Odile Oberlin
Purpose For over 30 years, the place of consolidation high-dose chemotherapy in Ewing sarcoma (ES) has been controversial. A randomized study was conducted to determine whether consolidation high-dose chemotherapy improved survival in patients with localized ES at high risk for relapse. Methods Randomization between busulfan and melphalan (BuMel) or standard chemotherapy (vincristine, dactinomycin, and ifosfamide [VAI], seven courses) was offered to patients if they were younger than 50 years of age with poor histologic response (≥ 10% viable cells) after receiving vincristine, ifosfamide, doxorubicin, and etoposide (six courses); or had a tumor volume at diagnosis ≥ 200 mL if unresected, or initially resected, or resected after radiotherapy...
September 6, 2018: Journal of Clinical Oncology